Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type

This study has been completed.
Sponsor:
Collaborator:
Aventis Pharmaceuticals
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT00190411
First received: September 13, 2005
Last updated: January 15, 2013
Last verified: March 2007